<DOC>
	<DOCNO>NCT02321436</DOCNO>
	<brief_summary>The purpose study investigate early administration ( i.e . within 12 week stroke ) Dysport® 500 U injection may delay appearance progression upper limb symptomatic spasticity .</brief_summary>
	<brief_title>Study Assess Impact Dysport Injections Early After Stroke Upper Limb Spasticity Progression</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>2 12 week first ever stroke accord World Health Organisation criterion ( previous transient ischaemic attack clinically silent infarct computerise tomography ( CT ) /magnetic resonance imaging ( MRI ) count previous stroke ) Stroke confirm CT/MRI scan classify ischaemic/haemorrhagic stroke Presence spasticity , either symptomatic , base symptomatic spasticity criterion ( i.e . least one follow item : impact passive/active function , involuntary movement pain ≥4 numeric pain rating scale [ NPRS ] ) symptomatic relevant upper limb Neuromuscular junction ( NMJ ) diseases , neurological disorder ( include prior local joint , tendon , intrinsic muscle disorder ) could potentially interfere assessment spasticity primary target muscle group select Investigator agreement subject Currently receive drug affect NMJ transmission e.g . aminoglycosides , aminoquinolines , cyclosporine , D penicillamine Previous surgery affect muscles/ ligaments/tendons Severe comorbidities ( e.g . congestive heart failure , myocardial infarction , multiple organ failure , hepatic renal failure , severe infection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>